US Patent Issued to Resverlogix on Feb. 17 for "Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor" (Canadian Inventors)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,551,484, issued on Feb. 17, was assigned to Resverlogix Corp. (Calgary, Canada).

"Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor" was invented by Kenneth Eugene Lebioda (Calgary, Canada), Christopher Ross Armstrong Halliday (Calgary, Canada) and Aziz Naeem Khan (Calgary, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described herein are methods of for treating and/or preventing Major adverse cardiovascular events (MACE). by administering to a subject in need thereof, a combination of a sodium-glucose transp...